Read Verzenio Treatment Information and Important Safety Considerations

Verzenio, also known by its generic name abemaciclib, is a prescription medicine used for certain types of hormone receptor positive and HER2 negative breast cancer. Understanding how this treatment is used and what safety considerations may apply can help patients and caregivers have informed conversations with healthcare professionals.

Verzenio is a kinase inhibitor used in specific patients with hormone receptor positive and HER2 negative breast cancer. According to current U.S. prescribing information, it may be used with endocrine therapy for certain high risk early breast cancer and in specific advanced or metastatic breast cancer settings. The appropriate treatment plan depends on individual medical circumstances and should be determined by a qualified healthcare professional.

Understanding Verzenio Treatment Information

Verzenio works by inhibiting cyclin dependent kinases 4 and 6, proteins involved in regulating cell growth. By interfering with these pathways, the medicine can help slow the growth of certain breast cancer cells. Treatment may involve Verzenio with an aromatase inhibitor, tamoxifen, or fulvestrant, depending on the approved treatment setting and the healthcare professional's recommendation.

Important treatment considerations include:

• Verzenio is taken orally according to the prescribed schedule.
• The dose may need adjustment or interruption when certain side effects occur.
• Diarrhea is a common and important adverse effect that may require prompt management.
• Blood counts may need monitoring because neutropenia can occur during treatment.
• Liver function tests are recommended before and during treatment.
• Patients should discuss all prescription medicines, nonprescription medicines, and supplements with their healthcare professional because drug interactions may affect treatment.
• Treatment decisions should be based on the patient's cancer type, treatment history, overall health, and other medications.

Patients should follow their prescribed instructions carefully and should not change, stop, or restart treatment without discussing it with their healthcare professional.

Important Safety Considerations for Verzenio

Verzenio has several important warnings and precautions. The current prescribing information identifies diarrhea, neutropenia, interstitial lung disease or pneumonitis, hepatotoxicity, venous thromboembolism, and embryo fetal toxicity among the key safety concerns.

Patients and caregivers should be aware of symptoms that may require medical attention, including:

• Severe or persistent diarrhea, particularly when accompanied by weakness or signs of dehydration.
• Fever or other signs of infection, which may be important when blood cell counts are reduced.
• New or worsening cough, shortness of breath, or difficulty breathing, which may indicate lung inflammation.
• Yellowing of the skin or eyes, dark urine, or other symptoms that could suggest liver problems.
• Swelling, pain, or tenderness in an extremity, or sudden chest pain and difficulty breathing, which may indicate a blood clot.
• Pregnancy or the possibility of pregnancy, because Verzenio may cause fetal harm.

The prescribing information recommends liver function monitoring before treatment and at specified intervals during therapy. Effective contraception is advised for females of reproductive potential during treatment and for at least three weeks after the final dose. Breastfeeding is also not recommended during treatment.

Verzenio is an important treatment option for certain patients with hormone receptor positive and HER2 negative breast cancer. Understanding its uses, monitoring requirements, possible side effects, and important safety warnings can help patients recognize concerns and communicate effectively with their healthcare team. This information is provided for educational purposes only and is not intended to replace professional medical advice, diagnosis, or individualized treatment recommendations.